АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология

Суставы. Примечание. Э — счёт эрозий; С — счёт сужений

Стопы

1МФС(Э,С) 1-УПлФС(Э,С)

Примечание. Э — счёт эрозий; С — счёт сужений. При этом:

Таблица 26.

Счёт эрозий (Э)

0 баллов

1 балл

2-5(2-10) баллов

Отсутствие эрозий

Дефект поверхности кости

Более глубокий дефект или большее число дефектов поверхности кости

• Метод Ларсена-Дейла (табл. 27) С помощью этого метода описывают­ся пять степеней повреждения суста­вов кистей и стоп при РА. Существуют стандартные рентгенограммы степеней повреждения для каждого оценивае­мого сустава. Максимальный счёт в одном суставе составляет 5 баллов. При подсчете общего счёта суммируется количество баллов в каждом суставе, при этом количество баллов в суета-Таблица 27.

вах запястий умножается на 5. Макси­мальный общий счёт для одного паци­ента (индекс Ларсена—Дейла) состав­ляет 200 баллов.

EULAR" рекомендует использовать ме­тод Ларсена, когда изменения оценива­ются несколькими исследователями. Если оценку деструкции проводит один специалист, лучше применять модифици­рованный метод Шарпа (более чувстви­тельный).

ЛИТЕРАТУРА

1. Harris E.D.Jr. Rheumatoid Arthritis:
pathophysiology and implications fortherapy
// N. Engl. J. Med. - 1990. - Vol. 322. -
R 1277-1289.

2. Gabriel S.E. The epidemiology of rheu­
matoid arthritis // Rheum. Dis. Clin. North
Am. - 2001. - Vol. 27. - P. 269-281.

3. Majka D.S., Holes V.M. Can we accurately
predict the development of rheumatoid arth­
ritis in the preclinical phase? // Arthri­
tis Rheum. - 2003. - Vol. 48. -
R 2701-2705.

4. Сигидин Я.А., Лукина Г.В. Ревматоид­
ный артрит. - М.: АНКО, 2001. - 328 с.

5. Lee DM., Weinblatt М.Е. Rheumatoid
arthritis // Lancet. - 2001. - Vol. 358. -
P. 903-911.

6. KlippelJ., Dieppe P. Rheumatology. - St
Louis: Mosby-Year Book, 1998.

7. Maddison P.J., Isenberg D., Woo P.
Oxford Textbook of Rheumatology. — Oxford:
Oxford University Press, 1998.

8. Ruddy S., HarrisE.D., Sledge C.B. Kelly's
Textbook of Rheumatology. - Philadelphia:
WB. Saunders, 2001.

9. American College of Rheumatology and
Hoc Committee on Clinical Guidelines.
Guidelines for the initial evaluation of the
adult patients with acute musculoskeletal
symptoms // Arthritis Rheum. - 1996. -
Vol.39.-P. 1-8.

10. American College of Rheumatology
Subcommittee on Rheumatoid Arthritis
Guidelines. Guidelines for the Management
of Rheumatoid Arthritis. 2002 Update //
Ibid. - 2002. - Vol. 46. - P. 328-346.

11. EULAR handbook of clinical assessment
in rheumatoid arthritis. - Van Zuiden, 2001.

12. BackhausM., Kamradt Т., Sandrock D.
et at. Arthritis of the finger joints: a
comprehensive approach comparing
conventional radiography, scintigraphy,
ultrasound, and contrast-enhanced mag­
netic resonance imaging // Arthritis Rhe­
um. - 1999. - Vol. 42. - P. 1232-1245.

13. Wakefield R.J., Gibbon W.W., Co-
naghan P.G. et al. The value of sonography
in the detection of bone erosions in patients
with rheumatoid arthritis: a comparison with

Ревматоидный артрит ♦ 59

conventional radiography//ibid. - 2000. -Vol. 43. - P. 2762.

14. Kerns W.F., Dijkmans B.A. Should we
look for osteoporosis in patients with rhe­
umatoid arthritis? // Ann. Rheum. Dis. —
2001.-Vol. 44. -P. 1496-1503.

15. Haugeberg G., Orstavic R.E., Uhling T.
et al. Clinical decision rules in rheumatoid
arthritis: do they identify patients at high risk
for osteoporosis? Testing clinical criteria in
a population based cohort of patients with
rheumatoid arthritis recruited from the Oslo
Rheumatoid Arthritis Register // Ibid. -
2002.-Vol. 61.-P. 1085-1089.

16. Arnrett F.C., Edworth S.M., Block D.A.
et al. The American Rheumatism Association
1987 revised criteria for the classification of
rheumatoid arthritis // Arthritis Rheum. -
1988. -Vol. 31,-R 315-324.

17. Harrison B.J., Symmons D.P.M., Barrett
EM., Silman A.J. The performance of the
1987 ARA classification criteria for the
rheumatoid arthritis in a population based
cohort of patients with early inflammatory
polyarthritis //J. Rheumatol. - 1998. -Vol.
26. - P. 2324-2330.

18. Algoritms for the Diagnosis and
Management of Musculoskeletal Condi­
tions. www3.utsouthwestern.edu/cme/
endurmat/lipsky.index.html

19. Chan K.-Wa., Felson D.T., Yood R.A.,
Walker A.M. The lag time between onset of
symptoms and diagnosis of rheumatoid
arthritis // Arthritis Rheum. - 1997. - Vol.
350. -P. 309-318.

20. Emery P., Breedveld F. С, Dougados M.
et al. Early referral recommendation for
newly diagnosed rheumatoid arthritis: evi­
dence based development of a clinical guide
//Ann. Rheum. Dis. - 2002. - Vol. 61. -
P. 290-297.

21. Anderson R.B., Needleman R.D., Gatter
R.A. et al. Patient outcome following inpa-
tient vs. outpatient treatment of rheuma­
toid arthritis //J. Rheumatol. - 1988. -
Vol. 15. -P. 556-560.

22. Helewa A., Bombardier C. Goldsmith
C.H. et al. Cost-effectiveness of inpatient and
intensive outpatient treatment of rheumatoid
arthritis. A randomized, controlled trial //

60 ♦ Ревматология ♦ Ревматоидный артрит

Arthritis Rheum. - 1989. - Vol. 32. -R 1505-1514.

23. Lambert СМ., Hurst N.P., Forbes J.F. et
al. Is day care equivalent to inpatient care
for active rheumatoid arthritis? Randomized
controlled clinical and economic evaluation
//BMJ. - 1998. -Vol.316. -R 965-969.

24. Vliet Vlieland T.P., Breedveld F.C.,
Hazes J.M. The two-year follow-up of a ran­
domized comparison of in patient multi-
disciplinary team care and routine out patient
care for active rheumatoid arthritis // Br. J.
Rheumatol. - 1997. - Vol. 36. - R 82-85.

25. Criswell L.A., Such C.L., Yelin E.H.
Differences in the use of second-line agents
and prednisone for treatment of rheumatoid
arthritis by rheumatologists and non-rheu-
matologists //J. Rheumatol. - 1997. -
Vol. 24. - P. 2290.

26. Yelin E.H., Such C.L., Criswell L.A.,
Epstein W.V. Outcomes for persons with
rheumatoid arthritis with a rheumatologist
versus a non-rheumatologist as the main
physician for this condition // Med Care. —
1998. -Vol.36. -R 513-522.

27. Ward M.M., Leigh J.P., Fries J.F.
Progression of functional disability in pati­
ents with rheumatoid arthritis. Associations
with rheumatology subspecialty care //
Arch. Intern. Med. - 1993. - Vol. 153. -
P. 2229-2237.

28. Solomon D.H., Bates D.W., Panush
R.S., KatzJ.N. Costs, outcomes, and patient
satisfaction by provider type for patients with
rheumatic and musculoskeletal conditions:
a critical review of the literature and proposed
methodologic standards // Ann. Intern.
Med. - 1997. - Vol. 127. - P. 52-60.

29. SaagK.C, Gerhan J.R., Kolluri S. et al.
Cigarette smoking and rheumatoid arthritis
severity // Ann. Rheum. Dis. - 1997. —
Vol. 56. - P. 463-469.

30. Harrison B.J., Silman A., Wiles N.J. et
al. Association of cigarette smoking with
disease outcome in patients with early in­
flammatory polyarthritis // Arthritis Rhe­
um. - 2001. - Vol. 44. - P. 323-330.

31. Cleland L.G., Hill C.L, James M.J. Diet
and arthritis // Baillieres Clin. Rheuma­
tol. - 1995. -Vol.9. - P. 771.

32. Pattison D.J., Harrison R.A., Symmons
D.P.M. The role of diet in susceptibility to
rheumatoid arthritis: a systemic review //
J. Rheumatol. - 2004. - Vol. 31. -
P. 1310-1319.

33. Riemsma R.P., Kirwan J.R., Taal E.,
Rasker J.J. Patient education for adult with
rheumatoid arthritis // Cochrane Database
Syst. Rev. - 2002.

34. Warsi A., LaValley M.P., Wang P.S. et
al. Arthritis self-management education
programs: a meta-analysis of the effect on
pain and disability // Arthritis Rheum. —

2003. - Vol. 48. - P. 2207.

35. Hakkinen A., Sokka Т., Kotaniemi A.,
Hannonen P. A randomized two-year study
of the effects of dynamic strength training on
muscle strength, disease activity, functional
capacity, and bone mineral density in early
rheumatoid arthritis // Ibid. - 2001. -
Vol.44. -P. 515.

36. Stenstrom C.H. Therapeutic exercise in
rheumatoid arthritis //Arthritis Care Res. —
1994. -Vol.7. - R 190.

37. van den Ende C.H., Vliet Vlieland T.P.,
Munneke M., Hazes J.M. Dynamic exer­
cise therapy for rheumatoid arthritis //
Cochrane Databa'se Syst. Rev. - 2000.
CD000322.

38. de Jong Z., Munneke M., Zwinderman
A.H. et al. Is a long-term high-intensity
exercise program effective and safe in pa­
tients with rheumatoid arthritis? Results of
a randomized controlled trial // Arthritis
Rheum. - 2003. - Vol. 48. - P. 2415.

39. van den Ende C.H.M., Vilet Vlieland
T.P.M., Munneke M., Hazes J.M.W. Dy­
namic exercise therapy for treating rheu­
matoid arthritis // The Cochrane Library. -

2004. - Vol. 2.

40. Westby M.D., Wade J.P., Rangno K.K.,
Berkowitz J. A randomized controlled trial
to evaluate the effectiveness of an exercise
program in women with rheumatoid arthri­
tis taking low dose prednisone // J. Rheu­
matol. - 2000. - Vol. 27. - Vol. 1674.

41. Robinson V., Brosseau L., Casimiro L.
et al. Thermotherapy for treating rheumatoid
arthritis // Cochrane Database Syst. Rev. -
2002. CD002826.

42. Casimiro L., Brosseau L., Robinson V.
et al. Therapeutic ultrasound for the tre­
atment of rheumatoid arthritis // Ibid. —
D003787.

43. Brosseau L, Welch V., Wells G. et al.
Low level laser therapy (classes I, II and III)
for treating rheumatoid arthritis // The
Cochrane Library. - 2004. - Vol. 2.

44. Robinson V., Brosseau L., Casimiro L.
et al. Thermotherapy for treating rheumatoid
arthritis // Ibid.

45. Steultjens E.M., DekkerJ., BouterLM.
et al. Occupational therapy for rheumatoid
arthritis: a systematic review // Arthritis
Rheum. - 2002. - Vol. 47. - P. 672.

46. Verhagen A.P., Bierma-Zeinstra
S.M.A., Cardoso J.R. et al. Balneotherapyfor
rheumatoid arthritis // The Cochrane
Library. - 2004. - Vol. 2.

47. Steultjens E.M.J., Dekker J., Bouter
L.M. et al. Occupational therapy for rheu­
matoid arthritis // Ibid.

48. Chalmers A.C., Busby C, Goyert J. et
al. Metatarsalgia and rheumatoid arthritis —
a randomized, single blind, sequential trial
comparing 2 types of foot orthroses and sup­
portive shoes // J Rheumatol. — 2000. —
Vol.27. -P. 1643.

49. Suarez-Almazor M.E., OsiriM., Emery
P., Ottawa Methods Group. Rheumatoid
arthritis // Evidence-Based Rheumatolo­
gy / Ed. P. Tugwell et al. - BMJ Dook,
2004.-P. 243-314.

50. Breedveld F.C., Kalden J.R. Appropriate
and effective management of rheumatoid
arthritis // Ann. Rheum. Dis. - 2004. -
Vol. 63. - P. 627-633.

51. О Dell J.R. Therapeutic strategies for
rheumatoid arthritis // N. Engl. J. Med. -
2004. - Vol. 350. - P. 2591-2602.

52. Management of Early Rheumatoid
Arthritis. A National Clinical Guideline.
Scottish Intercollegiate Guidelines Network.
www.sing.ac.uk

53. Quinn M.A., Conaghan P.G., Emery P.
The therapeutic approach of early
intervention for rheumatoid arthritis: what is
the evidence? // Rheumatology (Oxford). -
2001. -Vol. 40.-P. 1211-1220.

54. Mottonen Т., Наппопеп P., Korpela M.
et al. Delay to institution of therapy and

Ревматоидный артрит ♦ 61

induction of remission using single-drug or combination-disease-modifying anti-theumatic drug therapy in early rheumatoid arthritis // Arthritis Rheum. - 2002. -Vol. 46. - P. 894-898.

55. Anderson J.J., Wells G., VerhoevenA.C,
Felson D.T. Factors predicting response to
treatment in rheumatoid arthritis. The im­
portance of disease duration // Ibid. -
2000. - Vol. 43. - P. 22-29.

56. Buckland-Wright J.C., Clarke G.S.,
Chikanza l.C, Grahame R. Quantitative
microfocal radiography detects changes in
erosion area in patients with early rheumatoid
arthritis treated with myocrisine // J. Rhe­
umatol. - 1993. - Vol. 20. - P. 243-247.

57. Egsmose C, Lund В., Borg G. et al.
Patients with rheumatoid arthritis benefit
from early 2nd line therapy: 5 year follow-up
of a prospective double blind placebo cont­
rolled study // Ibid. - 1995. - Vol. 22. -
P. 2208-2213.

58. Munro R., Hampson R., McEntegart A.
et al. Improved functional outcome in
patients with early rheumatoid arthritis
treated with intramuscular gold: results of a
five year prospective study // Ann. Rheum.
Dis. - 1998. - Vol. 57. - P. 88-93.

59. Tsakonas £., Fitzgerald A.A., Fitz-
charles M.A. et al. Consequences of delayed
therapy with second-line agents in
rheumatoid arthritis: a 3 year follow-up on
the hydroxychloroquine in early rheumatoid
arthritis (HERA) study // J. Rheumatol. -
2000. - Vol. 27. - P. 623-629.

60. van derHeideA., JacobsJ.W.G., Bijlsma
J.W.J. et al. The effectiveness of early tre­
atment with «second-line» antirheumatic
drugs: a randomized, controlled trial //Ann.
Intern. Med. - 1996. - Vol. 124. - P. 699-
707.

61. LardL.R., VisserH., Speyerl. et al. Early
versus delayed treatment in patients with
recent-onset rheumatoid arthritis:
comparison of two cohorts who received
different treatment strategies//Am. J. Med.
-2001. -Vol. 111. - P. 446-451.

62. Nell V.P.K., Machold K.P., Eberl G. et
al. Benefit of very early referral and very early
therapy with disease-modifying anti-

62 •» Ревматология ♦ Ревматоидный артрит

rheumatic drugs in patients with early rheumatoid arthritis // Rheumatology. — 2004. - Vol. 43. - P. 906-914.

63. Furst D.E. Are there differences among
nonsteroidal anti-inflammatory drugs?
Comparing acetylated salicylates, non-
acetylated salicylates, and nonacetylated
nonsteroidal anti-inflammatory drugs //
Arthritis Rheum. - 1994. - Vol. 37. -
P. 1-9.

64. Brooks P.M., Day R.O. Nonsteroidal
anti-inflammatory drugs - differences and
similarities // N. Engl. J. Med. - 1991. -
Vol. 324. -R 1716-1725.

65. Fitzgerald G.A., Patrono С The Coxibs,
selective inhibitors of cyclooxygenase-2 //
Ibid. - 2001. - Vol. 345. - P. 433-442.

66. Wienecke Т., Gotzche P.O. Paracetamol
versus nonsteroidal anti-inflammatory drugs
for rheumatoid arthritis // Cochrane Library.
- 2004. - Vol. 2.

67. Paulus H.E., Di Primeo D., Sharp J.R.
et al. Patient retention and hand-wrist
radiograph progression of rheumatoid
arthritis during a 3-year prospective study
that prohibited DMARD//J. Rheumatol. -
2004. - Vol. 31 (in press).

68. Saag KG., Oliveri J.I., Patino F. et al.
Measuring quality in arthritis Care; the
Arthritis Foundation's quality indicator set
for analgetics // Arthritis Rheum. (Arthritis
Care and Res.). - 2004. - Vol. 51. -
P. 337-349.

69. Bombardier C. An evidence-based
evaluation of the gastrointestinal safety of
coxibs//Am. J. Med. - 2002. - Vol. 89. -
Suppl. 3D-9D National Institute of Clinical
Exellence. Guidlance on the use of cyclo-
oxygenase (COX) II selective inhibitors,
celecoxib, rofecoxib, meloxicam and etodo-
lac for osteoarthritis and rheumatoid arth­
ritis. Technology Apprasial Guidlance -
No. 27. London Goverment publication,
2001.

70. Garner S., Fidan O., Prankish R. et al.
Celecoxib for rheumatoid arthritis //
Cochrane Database Syst. Rev. - 2003. -
N4. 0D003831.

71. Simon L.S., Smolen J.S., Abramson
S.B. et al. Controversies in COX-2 selective

inhibition // J. Rheumatol. - 2002. -Vol. 29.-P. 1501-1510.

72. Hernandes-Diaz S., Garcia Rodriguez
L.A. Association between non-steroidal anti-
inflammatory drugs and upper gastro­
intestinal tract bleeding/perforation //
Arch. Intern. Med. - 2000. - Vol. 160. -
P. 2093-2099.

73. Jonson A.G., Nguyen T.V., Day R.O. Do
nonsteroidal anti-inflammatory drugs affect
blood pressure? A meta-analysis// Ann. In­
tern. Med. - 1994. -Vol. 121. - P. 289-300.

74. Gurwitz J.H., Avorn J., Bohn R.L et al.
Initiation of antihypertensive treatment
during nonsteroidal anti-inflammatory drug
therapy // JAMA. - 1994. - Vol. 272. -
R 781-786.

75. Heerdink E.R., Leufkens H.G., Herings
R.M. et al. NSAIDs associated with increased
risk of congestive heart failure in elderly
patients taking diuretics // Arch. Intern.
Med.- 1998. - Vol. 25. - P. 1108-1112.

76. Feenstra J., HeerdinkE.R., GrobbeD.E.,
Strieker B.H. Association of nonsteroidal
anti-inflammatory drugs with first occurrence
of heart failure and with relapsing heart
failure: the Rotterdam Study // Ibid. -
2002. - Vol. 162. - P. 265-270.

77. Weir M.R. Renal effects of nonselective
NSAIDs and coxibs// Cleve. Clin. J. Med. -
2002. - Vol. 69. - Supp. 1. - P. SI-53-
SI-58.

78. Whelton A. Renal and related
cardiovascular effects of conventional and
COX-2 - specific NSAIDs and non-NSAID
analgetics//Am. J. Then - 2000. - Vol. 7. -
R 63-74.

79. Strand V., Hochberg M.C. The risk of
cardiovascular thrombotic events with
selective cyclooxygenase-2 inhibitors //
Arthritis Rheum. (Arthritis Care and Res.). -

2002. - Vol. 47. - P. 349-355.

80. Baigent C., Patrono C. Selective cyc-
loxygenase 2 inhibitors, aspirin, and cardio­
vascular disease // Arthritis Rheum. —

2003. -Vol.48. - P. 12-20.

81. Wolfe M.M., Lichtenstein D.R., Singh
G. Gastrointestinal toxicity of nonsteroidal
anti-inflammatory drugs // N. Engl. J.
Med. - 1999. - Vol. 340. - P. 1888-1899.

82. Rostom A., Wells G., Tugwell P. et al.
Prevention of NSAlD-induced gastroduo-
denal ulcers (Cochrane Review) // The Co-
chrane Library. - 2002. - Is. 2. Oxford:
Update Software.

83. Gotzsche P.C., Johansen H.K. Meta-
analysis of short term low dose prednisolone
versus placebo and поп-steroidal anti-
inflammatory drugs in rheumatoid arthritis
//BMJ. - 1998. -Vol.316. -P. 811-818.

84. Harris E.DJr., EmkeyR.D., Nichols J.E.,
Newbwerg A. Low dose prednisolon therapy
in rheumatoid arthritis.: a double-blind study
// J. Rheumatol. - 1983. - Vol. 19. -
P. 1520-1526.

85. Milliom R., Poole P., Ketlegren J.H.,
Jayson M.I. Long-term study management
of rheumatoid arthritis // Lancet. — 1984. -
Vol. 1. -R 812-816.

86. Kirwan J.R. Arthritis and Rheumatism
Council Low-dose glucocorticoid study
group. The effect of glucocorticoids on joint
destruction in rheumatoid arthritis // N.
Engl. J. Med. - 1995. - Vol. 333. - P. 142-
145.

87. Boers M., Verhoeven A.C., Markusse
H.M. et al. Randomized comparison of
combined step-down prednisolon, metho-
trexate and sulphasalazine with sulpha-
salazine alone in early rheumatoid arthritis
// Lancet. - 1997. - Vol. 350. - P. 309-
318.

88. Hansen M., Podenphant J., Florescu A.
et al. A randomized trial of differentiated
prednisolone treatment in active rheumatoid
arthritis. Clinical benefits and skeletal side
effects//Ann. Rheum. Dis. - 1999. - Vol.
58,- P. 713-718.

89. Paulus H.E., di Primeo D., Sanda M. et
al. Progression of radiographic joint erosion
during low dose corticosteroid treatment of
rheumatoid arthritis // J. Rheumatol. —
2000. - Vol. 27. - P. 1632-1637.

90. VanEverdingerA.A., Jacobs J.W.G. etal.
Low dose prednisolone therapy for patients
with early active rheumatoid arthritis; clinical
efficacy, disease modifying propwerties and
side effects: a randomizes doubleOblind
placebo-controlled trial //Ann. Intern. Med. —
2002.-Vol. 136.-R 1-12.

Ревматоидный артрит ♦ 63

91. Capell N.A., Madhok R., HanterJ.A. et
al. on behave of the WOSERACT Group.
Lack of radiological and clinical benefit over
two years of low dose prednisolon for rheu­
matoid arthritis: results of a randomized
controlled trial // Ann. Rheum. Dis. -
2004. - Vol. 63. - P. 797-803.

92. Bae S.-C, Corzillius M., Kuntz KM.,
Liang M.H. Cost-effectiveness of low dose
corticosteroids versus non-steroidal anti-
inflammatory drugs and COX-2 specific
inhibitors in the long-term treatment of
rheumatoid arthritis // Rheumatology. -
2003. - Vol. 42. - P. 46-53.

93. Amin S., LaValtey M.P., Simms R.W.,
Felson D.T. The role of vitamin D in
corticosteroid -induced osteoporosis. A meta -
analytic Approach // Arthritis Rheum. -
1999.-Vol. 42, N8.-P. 1740-1751.

94. Recommendations for the prevention
and treatment of glucocorticoid-induced
osteoporosis: 2001 update. American Col­
lege of Rheumatology Ad Hoc Committee on
Glucocorticoid-induced Osteoporosis //
Ibid.-2001.-Vol. 44.-P. 1496.

95. Brown J.P., Josse R.G. for the Scientific
Advisory Council of the Osteoporosis Society
of Canada. Canadian guidelines for osteo­
porosis // CMAJ. - 2002. - Vol. 167. -
Suppl. 10. -S1-S34.

96. Hansen T.M., KrygerP., EllingH. et al.
Double blind placebo controlled trial of pulse
treatment with methylprednisolone
combined with disease modifying drugs in
rheumatoid arthritis//BMJ. - 1990. -Vol.
301. -R 268-270.

97. Liebling M.R., Leib £., Mclaughlin K.
et al. Pulse methylprednisolone in rheu­
matoid arthritis. A double-blind cross-over
trial//Ann. Intern. Med. - 1981. - Vol. 94. -
P. 21-26.

98.BirdH.A. Intra-articularand intralesional therapy // Oxford Textbook of Rheumatology / Eds J.H. KHppel, P.A. Nieppe. - St Louis: Mosby, 1994. - Ch. 16. - P. 16.1-16.6.

99. Fitzgerald O., Hanly J., Callan A. et al.
Effects of joint lavage on knee synovitis in
rheumatoid arthritis // Br. J. Rheumatol. —
1985. -Vol.24. -P. 6-10.

100. Chakravarty K., Pharoah P.O.P., Scott
D.G.I. A randomized controlled study of post -

64 «• Ревматология «■ Ревматоидный артрит

injection rest following intra-articularsteroid

therapy for knee synovitis // Ibid. — 1994. — Vol. 33. - R 464-468.

101. Guipcar Group. Clinical Practical
Guidlineforthe Management of Rheumatoid
Arthritis. — Madrid: Spanish Soc
Rheumatol, 2001. - 146 p.

102. Pincus Т., Ferraccioli G., Sokka T. et
al. Evidence from clinical trials and long-
term observational studies that disease-
modifying anti-rheumatic drugs slow
radiographic progression in rheumatoid
arthritis: updating a 1983 // Rheumatology.
- 2002. - Vol. 42. - R 1346-1356.

103. Jones G., Halbert J., Crotty M. et al.
The effect of treatment on radiological
progression in rheumatoid arthritis: a
systemic review of randomized placebo-
controlled trials // Ibid. - 2003. - Vol. 42. -
R6-13.

104. Suarez-Almazor M.E., Belseck E.,
Shea B. et al. Methotrexate for rheumatoid
arthritis // Cochrane Database Syst. Rev. —
2000. - N 2. CD000957.

105. Suarez-Almazor M.E., Belseck E.,
Shea B. et al. Antimalarials for treating
rheumatoid arthritis // The Cochrane
Library. - 2002. - Vol. 2. Oxford.

106. Weinblatt M.E., Reda D., Henderson
W. at. al. Sulfasalazine treatment for
rheumatoid arthritis. A meta-analysis of 15
randomized trials// J. Rheumatol. — 1999.
-Vol.26. -P. 2123-2130.

107. Osiri M., Shea В., Robinson V. et al.
Leflunomide for the treatment of rheumatoid
arthritis: a systemic reviewand meta-analysis
//Ibid. - 2003. - Vol. 30. - P. 1183-1190.

108. Wells G., Haguenauer D., Shea B. et
al. Cyclosporin for rheumatoid arthritis //
The Cochrane Library. - 2000. - Vol. 3.
Cochrane Database Syst. Rev. - 2000. -
Vol. 3. CD00846.

109. Suarez-Almazor M.E., Spooner C,
Belseck E. Penicillamine for rheumatoid
arthritis // Cochrane Database Syst. Rev. -
2000. -Vol.2. CD001460.

110. Suarez-Almazor M.E., Spooner C,
Belseck E. Azathioprine for treating
rheumatoid arthritis. Cochrane Muscu-
loskeletal Group // Ibid. - 2002. - Is. 3.

111. Suarez-Almazor M.E., Belseck E.,
Schea B. et al. Cyclophosphamide for
treating Rheumatoid Arthritis (Cochrane
Review) // The Cochrane Library. - 2002.

- Is. 2. Oxford: Update Software.

112. Brumenauer В., Judd M., Cranney A.
et al. Infliximab for the treatment of
rheumatoid arthritis (Cochrane Review) //
Ibid. - 2004. - Vol. 2.

113. Ten WoldeS., BreedveldF.C., Hermans
J. et al. Randomized placebo-controlled
study of stopping second-line drugs in
rheumatoid arthritis // Lancet. — 1996. —
Vol. 347. - R 347-352.

114. Van Aken J., LardL.R., Le Cessie S. et
al. Radiological outcome after four years of
early versus delayed treatment strategy in
patients with recent onset rheumatoid
arthritis//Ann. Rheum. Dis. - 2004. - Vol.
63. - P. 274-279.

115. Verstappen S.M.M., Jacobs J.W.G.,
Bijlsma J.W.J. et al. Five-year follow-up of
rheumatoid arthritis patients after early
treatment with disease-modifying
antirheumatic drugs versus treatment
accordingto the pyramid approach in the first
year// Arthritis Rheum. - 2003. - Vol. 49.
-P. 1797-1807..

116. MolenaarE.f.H., VoskylA.E.,Dinasnt H.J. et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission // Ibid. - 2004. - Vol. 50.

- P. 36-42.

117. Felson D.T., Anderson J.J., Meenan
R.F. Use of short-term efficacy/toxicity trade
off to select second-line drugs in rheumatoid
arthritis. A meta-analysis of published
clinical trials // Ibid. - 1992. - Vol. 35. -
P. 1117-1125.

118. MaetzetA., Wong A., Strand V. et al.
Meta-analysis of treatment termination rates
among rheumatoid arthritis patients
receiving disease-modifying anti-rheumatic
drugs // Rheumatology. - 2000. - Vol. 39.
-R 975-981.

119. Grove М.1., Hassell A.B., Hay EM.,
Shadforth M.F. Adverse reactions to disease-
modifying anti-rheumatic drugs in clinical
practice // Q. J. Med. - 2001. - Vol. 94. -
P. 309-329.

120. Cappel H., Madhok R., Mclnnes I.B.,
Practical prescribe guidelines in rheumatoid
arthritis. — Lond.; N.Y.: Martin Dunitz,
2003.-214 p. /

121. BorchersA.T., Keen C.L., Cheema G.S.,
Gershwin M.E. The use of methotrexate in
rheumatoid arthritis // Semin. Arthritis
Rheum. - 2004. - Vol. 34. - P. 465-483.

122. Pincus Т., Yazici Y., Sokka T. et al.
Methotrexate as the «anchor drug» for the
treatment of early arthritis // Clin. Exp.
Rheumatol. - 2003. - Vol. 21. - Suppl. 31. -
P. S179-185.

123. Chou H.K., Hernan M.A., SeegerJ.D.
et al. Methotrexate and mortality in patients
with rheumatoid arthritis // Lancet. —
2002. -Vol.359. — R 1173—1177.

124. Krause D., Schleusser В., Herborn C,
Rau R. Response to methotrexate is
associated with reduced mortality in patients
with severe rheumatoid arthritis // Arthritis
Rheum. - 2000. - Vol.43. - P. 14-21.

125. Weinblatt M.E., Coblyn J.S., Fox D.A.
et al. Efficacy of low-dose methotrexate in
rheumatoid arthritis // N. Engl. J. Med. -
1985. - Vol. 312, N 13. - R 818-822.

126. Andersen P.A., West S.G., O'DellJ.R.
et al. (1985). Weekly pulse methotrexate in
rheumatoid arthritis. Clinical and immu-
nologic effects in a randomized, double-blind
study // Ann. Intern. Med. - 1985. -
Vol. 103. - R 489-496.

127. Thompson R.N., Watts C, Edelman J.
et al. (1984). A controlled two-centre trial of
parenteral methotrexate therapy for refractory
rheumatoid arthritis // J Rheumatol. -
1984. -Vol. 11. - R 760-763.

128. Williams H.J., Willkens R.F.,
Samuelson C.O.Jretal. Comparison of low-
dose oral pulse methotrexate and placebo in
the treatment of rheumatoid arthritis. A
controlled clinical trial // Arthritis Rheum.
- 1985.-Vol.28.-P. 721-730.

129. Tugwell P., Bennett K., Gent M.
Methotrexate in rheumatoid arthritis//Ann.
Intern. Med. - Vol. 107. - R 358-366.

130. Haagsma C, van Riel P., de long A.,
van de Putte L. Combination of sulpha-
salazine and methotrexate versus the single
components in early RA: a randomized
controlled double blind 52 week clinical trial

Ревматоидный артрит «• 65

// Br. J. Rheumatol. - 1997. - Vol. 36. -R 1082-1088.

131. DougadosM., Combe В., CantagrelA.
et al. Combination therapy in early rheu­
matoid arthritis: a randomized controlled
double blind 52 week clinical trial of sulpha-
salazine and methotrexate compared with the
single components // Ann. Rheum. Dis. —
1999. -Vol.58. -P. 220-225.

132. Jeurissen M., Boerbooms A., van de
Putte L. et al. Methotrexate versus azathio-
prine in the treatment of rheumatoid arthri­
tis//Arthritis Rheum. - 1991. - Vol. 34.
-R 961-972.

133. Weinblatt M.E., Kaplan H., Germain
B.F. et al. Low-dose methotrexate compared
with auranofinin adult rheumatoid arthritis
A thirty-six-week, double-blind trial //
Ibid. - 1990. - Vol. 33. - P. 330-338.

134. Rau R., Herborn G., Karger T. et al. A
double blind randomized parallel trial of
intramuscular methotrexate and gold sodium
thiomalate in early erosive rheumatoid arth­
ritis// J. Rheumatol. - 1991. - Vol. 18. -
R 328-333.

135. Strand V., Cohen S., Schiff M. et al.
Treatment of active rheumatoid arthritis with
leflunomide compared to placebo and metho­
trexate // Arch. Intern. Med. - 1999. -
Vol. 159. - R 2542-2550.

136. Rau R., Herborn G., Menninger H.,
SanghaO. Radiographic outcome after three
years of patients with early erosive rheu­
matoid arthritis treated with intramuscular
methotrexale or parenteral gold. Extension
of a one-year double-blind study in 174
patients// Rheumatology (Oxford). - 2002.
-Vol.41. - P. 196-204.

137. Cohen S., Cannon G.W., Schiff M. et
al. Two-year, blinded, randomized, controlled
trial of treatment of active rheumatoid
arthritis with leflunomide compared with
methotrexate. Utilization of Leflunomide in
the Treatment of Rheumatoid Arthritis Trial
Investigator Group // Arthritis Rheum. —
2001. - Vol. 44. - P. 1984-1992.

138. Drosos A.A., Voulgari P.V., Kalsaraki
A., ZikouA.K. Influence of cyclosporin A on
radiological progression in early rheumatoid
arthritis patients: a 42-month prospective

66 ♦ Ревматология о- Ревматоидный артрит

study// Rheumatol. Int. - 2000. - Vol. 19. -R 113-118.

139. Wegrzyn J., Adeleine P., Miossec P.
Better efficacy of methotrexate given by
intramuscular injection than orally in patients
with rheumatoid arthritis // Ann. Rheum.
Dis. - 2004. - Vol. 63. - P. 1232-1234.

140. Lambert СМ., Sandhu S., Lochead A.
et al. Dose escalation of parenteral metho­
trexate in active rheumatoid arthritis that has
been unresponsive to conventional dose of
methotrexate. A randomized, controlled trial
// Arthritis Rheum. - 2004. - Vol. 50. -
P. 364-371.

141. OtizZ., SheaB., Suarez-AlmazorM.E.
et al. The efficacy of folic acid and folinic
acid in reducing metotrexate gastrointesti­
nal toxicity in rheumatoid arthritis. A me-
taanalysis of randomized controlled trial //
J. Rheumatol. - 1998. - Vol. 25. -
R 36-43.

142. van EdeA.E., Laan R.F., Rood M.J. et
al. Effect of folic or folinic acid
supplementation on the toxicity and efficacy
of methotrexate in rheumatoid arthritis, a
forty-eight week, multicentre randomized,
double-blind, placebo-controlled study //
Arthritis Rheum. - 2001. - Vol. 44. -
R 1515-1524.

143. White S.L., Hughes R.A. Folate
supplementation and methotrexate treat­
ment in rheumatoid arthritis; a review //
Rheumatology. - 2004. - Vol. 43. -
P. 267-273.

144. Munro R., Morrison E., McDonald A. G.
et al. Effect of disease modifying agents I on
the lipid profiles of patients with rheumatoid
arthritis //Ann. Rheum. Dis. - 1997. -
Vol. 56. - R 374-377.

145. Canadian Consensus Conference on
Hydroxychloroquine // J. Rheumatol. —
2000. - Vol. 27. - P. 2919-2921.

146. Dougados M. Sulfasalazine // Therapy
of Systemic Rheumatic Disorders / Eds
L.B.A. van de Putte et al. - N.Y.: Marcel
Dekker, 1998. -P. 165.

147. Bax D.E., Amos R.S. Sulphasalazine in
rheumatoid arthritis: desensitising the
patient with a skin rash//Ann. Rheum. Dis.
- 1986. -Vol.45. - P. 139.

148. Pullar Т., Hunter J.A., Capell H.A.
Sulphasalazine in rheumatoid arthritis: a
double blind comparison of sulphasalazine
with placebo and sodium aurothiomalate //
Br. Med.J. - 1983.-Vol.287.-P. 1102-
1104.

149. Neumann V., Grindulis K., Hubbal S.
et al. Comparison between penicillamine and
sulphasalazine in rheumatoid arthritis // Br.
Med.J.- 1983.-Vol. 287.-R 1099-1102.

150. Finals R., Kaplan S.B., Lawson J.G.,
Hepburn B. Sulfasalazine in rheumatoid
arthritis. A double-blind, placebo-control­
led trial // Arthritis Rheum. - 1986. -
Vol.29.-P. 1427-1434.

151. Williams H.J., WardJ.R., Dahl S.L. et
al. A controlled trial comparingsulfasalazine,
gold sodium thiomalate, and placebo in
rheumatoid arthritis // Ibid. — Vol. 31. —
P. 702-713.

152. Nuver-Zwart I.H., van Riel P.L.C.M.,
van de Putte L.B.A., Gribnau F.W.J. A
double blind comparative study of sulpha­
salazine and hydroxychloroquine in rheu­
matoid arthritis: evidence of an earlier effect
of sulphasalazine // Ann. Rheum. Dis. -
1989.-Vol.48. -P. 389-389.

153. Capell H.A., MarabaniM.. Madhok R.
et al. Degree and extent of response to
sulphasalazine or penicillamine therapy for
rheumatoid arthritis: Results from a routi­
ne clinical environment over a two year peri­
od // Q. J. Med. - 1990. - Vol. 75. -
R 335-344.

154. Australian Multicentre Clinical Trial
Group. Sulfasalazine in early rheumatoid
arthritis//J. Rheumatol. - 1992. - Vol. 19.
-P. 1672-1677.

155. Hannonen P., Mottonen Т., Hakola
M., Oka M. et al. Sulfasalazine in early
rheumatoid arthritis. A 48-week double-
blind, prospective, placebo-controlled study
//Arthritis Rheum. - 1993. - Vol. 36. -
R 1501-1509.

156. Porter D.. Madhok R., Hunter J.A.,
Capell H.A. Prospective trial comparing the
use of sulphasalazine and auranofin as
second line drugs in patients with rheumatoid
arthritis//Ann. Rheum. Dis. - 1992. -
Vol.51. -P. 461-464.

157. Smolen J.S., Kalden J.R., Scott DL. et
al. Efficacy and safety of leflunomide
compared with placebo and sulphasalazine
in active rheumatoid arthritis: a double-blind,
randomized, multicentre trial // Lancet. —
1999. - Vol. 353. - R 259-266.

158. Chou E.H., Scott D.L, Kingsley G.H.
et al. Treating rheumatoid arthritis early with
disease modifying drugs reduce joint da­
mage: a randomized double blind trial of
sulphasalazine vs diclofenac sodium // Clin.
Exp. Rheumatol. - 2002. - Vol. 36. -
P. 1501-1509.

159. Cannon G.W., Holden W.L, JuhaeriJ.
et al. Adverse events with disease modifying
antirheumatic drugs (DMARD: a cohort
study of leflunomide compared with other
DMARD // J. Rheumatol. - 2004. - Vol.
31.-P. 1906-1911.

160. Empire Rheumatism Council. Gold
therapy in rheumatoid arthritis: final report
of a multicentre controlled trial //Ann. Rhe­
um. Dis. - 1961. - Vol. 20. - P. 315-334.

161. Cooperating Clinics Committee of the
American Rheumatism Association. A
controlled trial of gold salt therapy in
rheumatoid arthritis // Arthritis Rheum. —
1973. -Vol.6. -R 353.

162. SigkerJ.W., Duncan H., Ensign D.C.
Gold salts in the treatment of rheumatoid
arthritis. A double-blind study//Ann. Intern.
Med. - 1974.-Vol. 80.-R 21.

163. Pullar Т., Hunter J.A., Capell H.A.
Sulphasalazine in rheumatoid arthritis: a
double blind comparison of sulphasalazine
with placebo and sodium aurothiomalate //
Br. Med. J. - 1983. - Vol. 287. - P. 1102-
1104.

164. WardJ.R., WilliamsH.J.,EggerM.I. et
al. Comparison of auranofin, gold sodium
thiomalate and placebo in the treatment of
rheumatoid arthritis // Arthritis Rheum. -
1983.-Vol.26.-P. 1303-1313.

165. CapellH.A., Lewis D., Carey J. A three
year follow up of patients allocated to placebo,
or oral or injectable gold therapy for
rheumatoid arthritis // Ann. Rheum. Dis. —
1986.-Vol. 45. -P. 705-711.

166. WilliamsH.J., WardJ.R., DahlS.L. et
al. A controlled trial comparingsulfasalazine,
gold sodium thiomalate, and placebo in

Ревматоидный артрит ♦ 67

rheumatoid arthritis // Arthritis Rheum. — 1986. -Vol. 31.-P. 702-713.

167. Suarez-Almazor M.E., Fitzgerald A.,
Grace M., Russell A. A randomized
controlled trial of parenteral methotrexate
compared with sodium aurothiomalate
(Myochrysine®) in the treatment of rheu­
matoid arthritis//J. Rheumatol. - 1986. -
Vol. 15.-P. 753-756.

168. Morassut P., Goldstein R., Cyr M. et
al. Gold sodium thiomalate compared to low
dose methotrexate in the treatment of
rheumatoid arthritis - a randomized, double
blind 26 weeks trial // Ibid. - Vol. 16. -

P. 302-306.

169. Rau R., Herborn G., Menniger H..
Blechschmidt J. Comparison of intramus­
cular methotrexate and gold sodium
thiomalate in the treatment of early erosive
rheumatoid arthritis: 12 month data of
a double-blind parallel study of 174 patients
// Br. J. Rheumatol. - 1997. - Vol. 36. -
R 345-352.

170. ZeidlerHX, Kvien Т.К., Hannonen P.
et al. Progression of joint damage in early
active severe rheumatoid arthritis during 8
months of treatment: comparison of low-dose
cyclosporin and parenteral gold // Ibid. -
1998. -Vol.37. -P. 874-882.

171. MenningerH., Herborn G., Sander O.
et al. A 36 month comparative trial of
methotrexate and gold sodium thiomalate in
the treatment of early active and erosive rheu­
matoid arthritis//Ibid. - P. 1060-1068.

172. Hamilton J., Mclnnes I.B.. Thomson
E.A., Porter D. et al. Comparative study of
intramuscular gold and methotrexate in a
rheumatoid arthritis population from a so­
cially deprived area // Ann. Rheum. Dis. —
2001. -Vol.60. -P. 566-572.

173. Kvein Т.К., ZeidlerH.K, Hannonen P.
Long-term efficacy and safety of cyclosporin
A versus parental gold in early rheumatoid
arthritis: a three year study of radiological;
progression. Renal function, and arterial
hypertension // Ibid. - 2002. - Vol. 61. -
P. 511-616.

174. TNF- Alpha Inhibition in the Treatment
of Rheumatoid Arthritis / Ed. L.W Moreland,
P.Emery. -2003. - 180 p.

68 -о- Ревматология -о- Ревматоидный артрит

175. Furst D.E., BreedveldF.C., Kalden J.R.
et al. Updated consensus statement on biolo­
gical agents, specifically tumor necrosis
factor aa (TNFaa) blocking agents and
interleukin-1 receptor antagonist (IL-1 ra),
for the treatment of rheumatic disease, 2004.
Ann Rheum Dis 2004; 63 (Suppl II); H2-
iil2.

176. Breedveld F.C., Emery P., Keystone E.
et al. Infliximab in active early rheumatoid
arthritis//Ann. Rheum. Dis. - 2004. - Vol.
63. - P. 149-155.

177. St Clair E.W., van der Heijde
D.M.F.M., Smolen J.S. et al. Combination
of infliximab and methotrexate therapy for
early rheumatoid arthritis. A Randomi­
zed controlled trial // Arthritis Rheum. -
2004. - Vol. 50. - P. 3432-3443.

178. Elliott M.J., Maini R.N., Feldmann M.
et al. Treatment of rheumatoid arthritis
with chimeric monoclonal antibodies to
tumor necrosis factor a // Ibid. - 1993. -
Vol.36.-P. 1681.

179. Elliott M.J., Maini R.N., Feldmann M.
et al. Randomized double-blind comparison
of chimeric monoclonal antibody to tumour
necrosis factor alfa (cA2) versus placebo in
rheumatoid arthritis // Lancet. - 1994. -
Vol.34. -P. 1105-1110.

180. Kavanaugh A., St ClairE.W., McCune
W.J. et al. Chimeric anti-tumor necrosis
factor-alpha monoclonal antibody treatment
of patients with rheumatoid arthritis receiving
methotrexate therapy // J. Rheumatol. -
2000. - Vol. 27, N 4. - P. 841-850.

181. Maini R.N., Breedveld F. С, Kalden J.R.
et al. Therapeutic efficacy of multiple
intravenous infusions of anti-tumor necrosis
factor aa monoclonal antibody combined with
low-dose weekly methotrexate in rheumatoid
arthritis //Arthritis Rheum. - 1998. -
Vol. 41, N9. - P. 1552-1563.

182. Maini R., St Clair E.W., Breedveld F.
et al. Infliximab (chimeric anti-tumour
necrosis factor alpha monoclonal antibody)
versus placebo in rheumatoid arthritis
patients receiving concomitant methotrexate:
a randomised phase III trial. ATTRACT Study
Group // Lancet. - 1999. - Vol. 354,
N9194. - P. 1932-1939.

183. Lipsky P.E., van der Heijde DM., St
Clair E. W. et al. Infliximab and methotrexate
in the treatment of rheumatoid arthritis. Anti-
Tumor Necrosis Factor Trial in Rheumatoid
Arthritis with Concomitant Therapy Study
Group // N. Engl. J. Med. - 2000. - Vol.
343. - P. 1594.

184. Durez P., Nzeussey Toukop A.,
Lauwerus B.R. et al. A randomized
comparative study of the short-term clinical
and biological effects of intravenous pulse
methylprednisolon and infliximab in patients
with active rheumatoid arthritis despite
methotrexate treatment //Ann. Rheum. Dis.
- 2004. - Vol. 63. - P. 1069-1074.

185. Calabrese L.H., Zein N., Vassilopoulos
D. Safety of anti-tumor necrosis factor (anti-
TNF) therapy in patients with chronic viral
infection; hepatitis C, hepatitis В and HIV
infection // Ibid. - Suppl. II. - P. ii8-ii24.
186. HyrichK.L.SikmanAJ., WatsonK.D.,
SymmonsD.P.M. Anti-TNF (alpha) therapy
in rheumatoid arthritis. An update on safety
// Ibid.

187. Emery P., ReginsterJ.-Y., Appelboom
T. et al. WHO Collaborative Centre
consensus meeting on anti-cytokine therapy
in rheumatoid arthritis // Rheumatology. -
2001. - Vol. 40. - P. 699-670.

188. Khanna D., McMahon Al., Furst D.E.
Anti-tumor necrosis factor aa therapy and
heart failure // Arthritis Rheum. - 2004. -
Vol. 50.-P. 1040-1050.

189. Tumiati В., Casoli P., Veneziani M. et
al. High-dose immunoglobulin therapy as an
immunomodulatory treatment of rheumato­
id arthritis // Ibid. - 1992. - Vol. 103. -
P. 1126-1133.

190. Muscat C, Bertotto A., Ercolani R. et
al. Long term treatment of rheumatoid
arthritis with high doses of intravenous
immunoglobulins; effects on disease activity
and serum cytokines // Ann. Rheum.
Dis. - 1995. - Vol. 54. - P. 382-385.

191. Maksymowych W.P., Avina-Zubieta
A., Luong M. et al. High dose intravenous
immunoglobulin in severe refractory rheu­
matoid arthritis: no evidence of effectivity //
Clin. Exp. Rheumatol. - 1996. - Vol. 14. -
P. 657-660.

192. Kanik K.S., Yarboro C.H., Naparstec Y.
et al. Failure of low dose intravenous
immunoglobulin to suppress disease activity
in patients with treatment refractory rheu­
matoid arthritis//Arthritis Rheum. - 1996.
-Vol.39. -P. 1072-1029.

193. Zerkak D., Dougados M. Benefit/risk
of combination therapy // Clin. Exp. Rheu-
matol. - 2004. - Vol. 22. - Suppl. 35. -
P. S71-76.

194. Verhoeven A.C., Boers M., Tugwell P.
Combination therapy in rheumatoids arth­
ritis; updated systemic review// Br. J. Rheu-
matol. - 1998. - Vol. 37. - P. 612-619.

195. Tugwell P., Pincus Т., Yocum D. et al.
Combination therapy with cyclosporine and
methotrexate in severe rheumatoid arthritis
// N. Engl. J. Med. - 1995. - Vol. 333. -
P. 137-142.

196. Haagsma G.J., van Riel P., de Rooij
D.J. et al. Combination of methotrexate and
sulphasalazine vs methotrexate alone: a
randomized open clinical trial in rheumatoid
arthritis patients resistant to sulphasalazine
therapy//Br. J. Rheumatol. - 1994. -Vol.
33.-P. 1049-1055.

197. DougadosM., CombeB., CantagrelA.
et al. Combination therapy in early
rheumatoid arthritis: a randomized, cont­
rolled double blind 52—weeks clinical trial of
sulphasalazine and methotrexate compared
with the single component // Ann. Rheum.
Dis. - 1999. - Vol. 58. - P. 220-225.

198. Boers M., Verhoeven A.C., Matkusse
H.M. et al. Randomised comparison of
combined step-down prednisolon, metho­
trexate and sulphasalazine with sulphasa­
lazine alone in early rheumatoid arthri­
tis// Lancet. - 1997. - Vol. 350. - P. 309-
318.

/ 99. Mottonen Т., Наппопеп P., Leirisalo-Repo M. et al., the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis, a randomized trial // Ibid. — 1999. -Vol. 353.-P. 1568-1573. 200. Korpela M., Laasonen L., Наппопеп P. et al. Retardtion of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-

Ревматоидный артрит ♦ 69

modifying antirheumatic drugs // Arthritis Rheum. - 2004. - Vol. 50. - P. 2072-2081.

201. Puolakka K., Kautinen H., Mottonen
T. et al. Impact of initial aggressive drug
treatment with a combination of disease-
modifying antirheumatic drugs on the
development of work disability in early
rheumatoid arthritis // Ibid. - P. 55-62.

202. Proudman S.M., Conaghan P.G.,
Richardson С et al. Treatment of poorly-
prognosis early rheumatoid arthritis. A
randomized study treatment with methotre­
xate, cyclosporin A, and intraarticulat
corticosteroids compared with sulphasala­
zine alone // Ibid. - 2000. -. Vol. 43. -
P. 1809-1819.

203. Calguneri M., Pay S., CaliskanerZ. et
al. Combination therapy versus monotherapy
for the treatment of patients with rheumatoid
arthritis // Clin. Exp. Rheumatol. - 1999.
-Vol. 17.-P. 699-704.

204. KremerJ.M., Genovese M.C., Cannon
G.W.etal. Concominantleflunomide therapy
in patients with active rheumatoid arthritis
despite stable dose of methotrexate. A ran­
domized, double-blind, placebo-controlled
trial // Ann. Intern. Med. - 2002. -
Vol. 137.-P. 726-733.

205. O'DellJ.R., LeffR., Paulsen G. et al.
Treatment of rheumatoid arthritis with
methotrexate and hydroxychlorochine,
methotreaxate and sulphasalazine. or a
combination of three medications: results of
a two-year, randomized, double-blind,
placebo-controlled trial // Arthritis Rheum.
- 2002. - Vol. 46. - P. 1164-1170.

206. Landewe R.B., Boers M., Verhoeven
A.C. et al. COBRA combination therapy in
patients with early rheumatoid arthritis: long
term structural benefit of a brief intervention
// Ibid. - R 347-356.

207. Ferraccioli G.F., GremeseE., Tomietto
P. et al. Analysis of improvements, full
responses, remission and toxicity in
rheumatoid patients treated with step-up
combination therapy (methotrexate, cyc­
losporin A, sulphasalazine) or monotherapy
for three years//Rheumatology (Oxford). -
2002. -Vol.41. -P. 892-898.

70 •» Ревматология о- Ревматоидный артрит

208. Mailiefert J.F., Combe В., Goupille P.
et al. Long term structural effects of
combination therapy in patients with early
rheumatoid arthritis: five year follow up of a
prospective double blind controlled trial //
Ann. Rheum. Dis. - 2003. - Vol. 62. -
R 764-766.

209. Marchesoni A., Battafarano N.. Ar-
reghiniM. et al. Radiographic profession in
early rheumatoid arthritis: a 12-month
randomized controlled study comparing the
combination of cyclosporin and metho-
trexate with methotrexate alone // Rheu­
matology (Oxford). - 2003. - Vol. 62. -
P. 291-296.

210. GerardsA.H.,LandeweR.B.,PrinsA.P.
et al. Cyclosporin A monotherapy versus
cyclosporin A and methotrexate combination
therapy in patients with early rheumatoid
arthritis: a double blind randomized place­
bo controlled trial // Ann. Rheum. Dis. -
2003. - Vol. 62. -P. 291-296.

211. Ensmorth S. Anti-rheumatic medi-
catiobs during pregnancy and lactation
(Part 1)//J. Can. Rheum. Assoc. - Pt 1,2.

212. Jansen N.M., Genta M.S. The effects
of immunosuppressive and anti-inflam­
matory medications on fertility, pregnan­
cy, and lactation // Arch. Intern. Med. —
2000. -Vol. 160.-P. 610-619.

213. Pinals R.S. Drug therapy in Felty"s
syndrome // Up To Date. - 2002. -
Vol. 20. - P. 2.

214. Turesson C, Matterson E.L.
Management of extraarticular disease mani­
festations in rheumatoid arthritis // Curr.
Opin. Rheumatol. - 2004. - Vol. 16. -
P. 206-211.

215. Smolen J.S., Sokka Т., Pincus T.
A proposed treatment algoritm for
rheumatoid arthritis: aggressive therapy,
methotrexate, and quantitative supervisi­
on // Clin. Exp. Rheumatol. - 2003. -
Vol. 21. - Suppl. 31. - S209-S210.

216. Grigor C, Cappell H., McMacon A.D.
et al. Effect of a treatment strategy of tight
control for rheumatoid arthritis (the T1CORA
study): a single-blind randomized control­
led trial // Lancet. - 2004. - Vol. 364. -
P. 263-269.

217. Brennan P., Harrison В., Barrett E. et
al. A simple algorithm to predict the de­
velopment of radiological erosions in pati­
ents with early rheumatoid arthritis: prospec­
tive cohort study // BMJ. - 1996. -
Vol.313. -P. 471-476.

218. Combe В., Dougados M., Goupille P.
et al. Prognostic factors for radiographic
damage in early rheumatoid arthritis (RA): a
multiparameter, prospective study // Arth­
ritis Rheum. - 2001. - Vol. 44. - P. 1736-
1743.

219. Feigenbaum S.L, Masi A.T., Kaplan
S.B. Prognosis in rheumatoid arthritis. A

longitudinal study of newly diagnosed younger adult patients // Am. J. Med. -1979. - Vol. 66. - P. 377-384.

220. Gough A., Faint J., Salmon M. et al.
Genetic typing of patients with inflammatory
arthritis at presentation can be used to
predict outcome // Arthritis Rheum. -

1994. - Vol. 37. - P. 1166-1170.

221. Matanen Т., Palmela L., Leirisalo-
Repo M. et al. Only high disease activity and
positive rheumatoid factor indicate poor
prognosis in patients with early rheumatoid
arthritis treated with «sawtooth» strategy//
Ann. Rheum. Dis.'- 1998. - Vol. 57. -
P. 533-539.

222. van der Heide A., Remme C.A., Hof-
man DM. et al. Prediction of progression of
radiologic damage in newly diagnosed
rheumatoid arthritis // Arthritis Rheum. -

1995. -Vol.38. -P. 1466-1474.

223. van der Heijde D.M.F.M., van Riel
P.L.C.M., van Leeuwen M.A. et al. Pro­
gnostic factors for radiographic damage and
physical disability in early rheumatoid
arthritis. A prospective follow-up study of 147
patients // Br. J. Rheumatol. - 1992. -
Vol.31. -P. 519-525.

224. van der Horst-Bruinsma I.E., Speyer
I., Visser H. et al. Diagnosis and course of
early onset arthritis: results of a special early
arthritis clinic compared to routine patient
care//Ibid.- 1998. -Vol.37. - R 1084-1088.

225. van Leeuwen M.A., WestraJ., van Riel
P.L.C.M. et al. IgM, IgA, and IgG rheu­
matoid factors in early rheumatoid arthritis
predictive of radiological progression? //

Scand. J. Rheumatol. - 1995. - Vol. 24. -R 146-153.

226. van Zeben D., Hazes J.M.,
Zwinderman A.H. et al. Factors predicting
outcome of rheumatoid arthritis: results of a
follow-up study//J. Rheumatol. - 1993. -
Vol.20. -P. 1288-1296.

227. Bukhari Al, Lunt M., Harrison B.J. et
al. Rheumatoid factor is the major predictor
of increasing severity of radiographic erosions
in rheumatoid arthritis. Results from Nor­
folk Arthritis Register Study, a large co­
hort//Arthritis Rheum. - 2002. -Vol. 46. -
P. 906-912.

228. Rosandich P.A., KelleyJ.T., Conn D.L
Perioperative management of patients with
rheumatoid arthritis in the era of biologic
response modifiers // Curr. Opin. Rheu­
matol. - 2004. - Vol. 16. - P. 192-198.

229. Felson D.Т., Anderson J.J., BoersM. et
al. American College of Rheumatology
preliminary definition of improvement in
rheumatoid arthritis // Arthritis Rheum. -
1993. - Vol. 36. - P. 729-740.

230. Fries J.F., Spitz P.W., Young D.Y. The
dimensions of health outcomes: the Health
Assessment Questionnaire, Disability Pain
Scale//J. Rheumatol. - 1982. - Vol. 9. -
R 789-793.

231. Smolen J.S., Breedveld F.C., Schiff
M.H. et al. A simplified disease activity index
for rheumatoid arthritis for use in clinical
practice // Rheumatology. - 2003. - Vol.
42. -P. 144-257.

232. Pinals R.S., Masi A.T., Larsen R.A.,
and the Subcommittee for Criteria of
Remussion in Rheumatoid Arthritis of the
American Rheumatism Association Diag­
nostic and Therapeutic Criteria Committee.
Preliminary criteria for clinical remission in
rheumatoid arthritis // Arthritis Rheum. —
1981. - Vol.24. - P. 1308-1315.

233. FransenJ.,StuckiG., vanRielP.L.C.M.
Rheumatoid arthritis measures // Arhritis
Rheum (Arthritis Care and Res.). - 2003.
-Vol.49. -S214-S224.

234. Fransen J., Creemers C.W., van Riel
P.L.C.M. Remission in rheumatoid arthri­
tis: agreement of the disease activity score
(DAS28) with the ARA preliminary remission
criteria // Rheumatology. - 2004. - P. 1 -4.

Ревматоидный артрит ♦ 71

235. Pincus Т., Callahan L.F., Sale W.G. et
al. Severe functional decline, work disability.
And increased mortality in 75 rheumatoid
arthritis patients studied over 9 years //
Arthritis Rheum. - 1984. - Vol. 27. -
R 864-872.

236. Pincus Т., Brooks R.H., Callahan L.E.
Prediction of long-term mortality in patients
with rheumatoid arthritis according to simple
questionnaire and joint count measures //
Ann. Intern. Med. - 1994. - Vol. 120. -
R 26-34.

237. Pincus Т., Callahan L.F. What is the
natural history of rheumatoid arthritis //
Rheum. Dis. Clin. North Am. - 1993. -
Vol. l.-R 123.

238. Wolfe F., Pincus Т., O'Delt J. Eva­
luation and documentation of rheumatoid
arthritis disease status in the clinic: which
variables best predict change in therapy //
J. Rheumatol. - 2001. - Vol. 28. -
P. 1712-1717.

239. Solomon D.H., Karison E.W., Rimm
E.B. et al. Cardiovascular morbidity and
mortality in women diagnosed with
rheumatoid arthritis //Circulation. — 2003.
-Vol. 107.-P. 1303-1307.

240. Wolfe F, Preundlich В., Straus W.L.
Increase in cardiovascular and cerebrovas-
cular disease prevalence in rheumatoid arth­
ritis // J. Rheumatol. - 2003. - Vol. 30. -
P. 36-40.

241. Watson D.J., Rhodes Т., Guess H.A.
All-cause mortality and vascular events
among patients with rheumatoid arthritis,
osteoarthritis, or no arthritis in the UK
general practice research database // Ibid.
- P. 1196-1202.

242. Fischer L.M., Schlienger R.G., Matter
С et al. Effects of rheumatoid arthritis or
systemic lupus erythematosus on the risk of
first-time acute myocardial infarction // Am.
J. Cardiol. - 2004. - Vol. 93. - P. 198-
200.

243. Maradit-Kremers H., Crowson C.S.,
Nicola P.J. et al. Increased unrecognized
coronary heart disease and sudden deaths in
rheumatoid arthritis. A population-based
controlled study // Arthritis Rheum. - 2005.
-Vol.52. - P. 402-411.

АНКИЛОЗИРУЮЩИЙ СПОНДИЛИТ (БОЛЕЗНЬ БЕХТЕРЕВА)

Анкилозирующий спондилит (АС) -хроническое системное воспалительное заболевание, характеризующееся пре­имущественным поражением крестцо-во-подвздошных сочленений и позво­ночника.

АС относится к группе серонегативных спондилоартритов, куда включены так­же реактивные артриты, псориатичес-кий артрит, спондилоартриты при неспе­цифическом язвенном колите и болезни Крона, а также недифференцированные спондилоартриты. Этим заболеваниям свойственны следующие общие черты: несимметричный олигоартрит преиму­щественно нижних конечностей, энтези-ты, сакроилиит и поражение других от­делов позвоночника, а также передний увеит, аортит, наследственная предрас­положенность, частое наличие HLA-B27 и отсутствие РФ в сыворотке крови. МКБ-10: М08.1 Юношеский анкилози­рующий спондилит; М45 Анкилозирую­щий спондилит; М48.1 Анкилозирую­щий гиперостоз Форестье. Аббревиатура. АС — анкилозирующий спондилит.

Дата добавления: 2015-10-20 | Просмотры: 700 | Нарушение авторских прав